THE USE OF INTRAVITREAL STEROID IMPLANT(OZURDEX) FOR TREATMENT OF REFRACTORY CYSTOID MACULAR EDEMA SECONDARY TO RETINITIE PIGMENTOSA

AL MAMOORI FAWWAZ EYE SPECIALTY HOSPITAL, AMMAN, JORDAN

(No Financial Disclosure)



INTRODUCTION

Retinitis pigmentosa is a clinically & genetically diverse group of diffuse retinal dystrophies that initially affecting rod with subsequent degeneration of cones, Maculopathy is one of the complications of RP that affecting vision and usually takes different types 1.(Atrophic),2.(Cystoid Macular Edema) 3.(Macular retraction),

The prevalence of CME was 52% in AD RP, 39 % in AR RP and 35% in XL.

METHODS

We retrospectively review a 24y old male patient that presented with bilateral refractory cystoid macular edema secondary to RP which is not responding to topical carbonic anhydrase inhibitor and multiple anti VEGF injections of Lucentis in both eyes, the patient underwent bilateral 0.7 mg intravitreal dexamethason(OZURDEX) implant of 1 week apart, the spectral domain OCT was performed before and one month after OZURDEX injection and to assess the efficacy of intravitreal steroid implants in treatment of refractory CMO in RP.

RESULTS

The Spectral Domain OCT after 1 month of injection showed a significant anatomical and functional improvements, CMT improved from 314 um to 233 um in the right eye and from 590 um to 207 um in the left eye. The BCVA improved from 6/18 to 6/9 in the right eye and from CF 1 meter to 6/60 in the left eye.

CONCLUSION

It seems that the refractory CMO in RP is mostly inflammatory driven, for this reason it shows a dramatic response to intravitreal steroids, in our case, the patient has received multiple anti VEGF injections of Lucentis with no improvment, but he responded very well anatomically and functionally to intravitreal steroid implant of OZURDEX, the results in our case was matching other small case series results, EX: In retrospective study of Ozdemir et al reported the efficacy of intravitreal steroid in a group of five eye of five patients. Further preferably randomized trails may establish the place of intravitreal dexamethason in the treatment of refractory CME related to RP

ACKNOWLEGEMENT

This material based on our clinical practice in EYE SPECIALTY HOSPITAL (AMMAN, JORDAN), Any options, findings and conclusions or recommendations expressed in this material are those of author.




Fig A: COLOUR FUNDUS IMAGE, SHOWES
BONE SPECULES CHANGES OF
RETINITIS PIGMENTOSA




Fig B: OCT IMAGE FOR RIGHT EYE
BEFORE AND AFTER
OZURDEX INJECTION




Fig C :OCT IMAGE FOR THE LEFT EYE BEFORE AND AFTER OZURDEX INJECTION

REFERENCES

- 1. Heckenlively et al. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 1999;127:565–573.
 - 2. Yoshida et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013;120:100–105.
 - 3. Saatci et al. Bilateral Intravitreal Dexamethasone Implant for Retinitis Pigmentosa- Related Macular Edema. Case Rep Ophthalmol 2013;4:53–58.
- 4. Alhassan M and Quintyn JC. Unilateral intravitreal dexamethazone implant for bilateral retinitis pigmentosa-related macular edema. Graefes Arch Clin Exp Ophthalmol 2013;251:2827–2828.
- 5. Srour et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2013;251:1501–1506, 1. Ikeda Y, Hisatomi T, Yoshida N, Notomi S, Murakami Y, Enaida H, Ishibashi T. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp

6. Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol.

7. Spalton DJ, Bird AC, Cleary PE. Retinitis pigmentosa and retinal oedema. Br J Ophthalmol. 1978;62:174–182.